Results 71 to 80 of about 75,341 (263)
Treatment-resistant schizophrenia criteria.
, 2023 Treatment-resistant schizophrenia refers to cases in which the symptoms of schizophrenia persist despite adequate and sufficient treatment with antipsychotics. The mechanisms that explain why some patients do not experience improvement in their symptoms with conventional treatment are not fully understood.
Bravo, Josselyn Anjhela +7 more
openaire +1 more source
Cannabinoids and drug–drug pharmacokinetic interactions: Deciphering the risks
British Journal of Clinical Pharmacology, EarlyView.The relationship between cannabinoids and mental health has become a major focus of scientific inquiry and public discourse. Cannabinoids are diverse chemical compounds from the Cannabis species that have been explored for their therapeutic applications in treating chronic pain, psychiatric and neurological conditions, such as depression, schizophrenia,
Paraskevi Papakyriakopoulou +2 more
wiley +1 more source
Role of aripiprazole in treatment-resistant schizophrenia
Neuropsychiatric Disease and Treatment, 2012 Nilufar Mossaheb,1 Rainer M Kaufmann21Department of Child and Adolescent Psychiatry, 2Department of Psychiatry and Psychotherapy, Medical University, Vienna, AustriaAbstract: About one third of patients with schizophrenia respond unsatisfactorily to ...
Mossaheb N, Kaufmann RM
doaj
The impact of beliefs about mental health problems and coping on outcome in schizophrenia. [PDF]
, 2004 Background. Using the theoretical framework of the Self Regulation Model (SRM), many studies have demonstrated that beliefs individuals hold about their physical health problems are important in predicting health outcomes.
Barrowclough, Christine +2 more
core +1 more source
Pharmacogenomics of Major Depressive Disorder in Indigenous Amazonian Populations
Clinical Pharmacology &Therapeutics, EarlyView.Major depressive disorder is a highly prevalent psychological disorder worldwide and its main treatment is the use of Selective Serotonin Reuptake Inhibitors. However, few studies have demonstrated the relationship between the presence of genetic variants in pharmacogenes and the efficacy of these drugs, especially in populations with a unique genetic ...
Kaio Evandro Cardoso Aguiar +9 more
wiley +1 more source
Enhancement of psychosocial treatment with D-cycloserine: models, moderators, and future directions [PDF]
, 2016 Advances in the understanding of the neurobiology of fear extinction have resulted in the development of d-cycloserine (DCS), a partial glutamatergic N-methyl-D-aspartate agonist, as an augmentation strategy for exposure treatment.
de Kleine, Rianne A. +8 more
core +1 more source
Clinical Pharmacology &Therapeutics, EarlyView.Maternal health remains a critical global concern, particularly in underserved populations and in low‐ and middle‐income countries where access to safe and effective therapeutics is limited. Despite the use of medications by most women during pregnancy, the exclusion of pregnant and lactating women from clinical trials has resulted in significant data ...
Rachel K. Scott +7 more
wiley +1 more source
Frontiers in PsychiatryBackgroundTreatment resistance in schizophrenia is a major clinical challenge. While autistic traits are often more pronounced in patients with treatment-resistant schizophrenia (TRS), limited data exist on clozapine-resistant schizophrenia (CRS).
Ahmet Selim Başaran +3 more
doaj +1 more source
Health related effects of wheat varieties [PDF]
, 2020 Summarises the different effects wheat digestion has on human ...
Borgen, Anders
core
Effects of haloperidol and atypical neuroleptics on psychomotor performance and driving ability in schizophrenic patients - Results from an experimental study [PDF]
, 2003 The influence of antipsychotic treatment on the neuropsychological and psychomotor performance of schizophrenic patients is still a subject of investigation.
Kagerer, S. +3 more
core +1 more source